Efficacy and Safety of Linaclotide in Elderly Patients
The efficacy and safety of linaclotide in elderly patients are poorly understood. Herein, we aimed to assess the efficacy and safety of linaclotide in elderly patients in real-world setting. We retrospectively enrolled consecutive patients who started linaclotide therapy at Sapporo Medical University Hospital from October 1, 2017 to December 31, 2019. The efficacy and safety of linaclotide were examined in relation to various factors, including age (<65 or ≥65 years) and dose (0.25 or 0.5 mg/d). Fifty-two patients were enrolled, 60% of whom were over 65 years old and 40% were female. Thirty-six patients received a linaclotide dose of 0.25 mg/d. The most common side effect was diarrhea, but there was no difference in the incidence of diarrhea between the elderly (64.5%) and non-elderly patients (42.9%, p=0.130). No significant difference was observed with respect to improvement in constipation in the elderly (83.9%) and non-elderly patients (71.4%, p=0.318). Additionally, the difference in efficacy of linaclotide in patients who received a reduced dose (80.6%) vs. those who received the recommended dose (75.0%) was not statistically significant (p=0.719). Multivariate analysis revealed that age, gender, and dose were not associated with diarrhea induced by linaclotide treatment. However, concurrent treatment with constipation-inducing medications [odds ratio (OR) 5.79, p=0.047] and linaclotide monotherapy (OR 11.1, p=0.040) were both risk factors contributing to diarrhea. Linaclotide is effective and safe for use in elderly patients. The incidence of diarrhea may increase when linaclotide is administered alone or concurrently used with medications that cause constipation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 141(2021), 2 vom: 22., Seite 255-262 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Ishigo, Tomoyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic constipation |
|---|
| Anmerkungen: |
Date Completed 20.05.2021 Date Revised 20.05.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1248/yakushi.20-00176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32079847X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32079847X | ||
| 003 | DE-627 | ||
| 005 | 20231225174401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1248/yakushi.20-00176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM32079847X | ||
| 035 | |a (NLM)33518646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Ishigo, Tomoyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Linaclotide in Elderly Patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2021 | ||
| 500 | |a Date Revised 20.05.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The efficacy and safety of linaclotide in elderly patients are poorly understood. Herein, we aimed to assess the efficacy and safety of linaclotide in elderly patients in real-world setting. We retrospectively enrolled consecutive patients who started linaclotide therapy at Sapporo Medical University Hospital from October 1, 2017 to December 31, 2019. The efficacy and safety of linaclotide were examined in relation to various factors, including age (<65 or ≥65 years) and dose (0.25 or 0.5 mg/d). Fifty-two patients were enrolled, 60% of whom were over 65 years old and 40% were female. Thirty-six patients received a linaclotide dose of 0.25 mg/d. The most common side effect was diarrhea, but there was no difference in the incidence of diarrhea between the elderly (64.5%) and non-elderly patients (42.9%, p=0.130). No significant difference was observed with respect to improvement in constipation in the elderly (83.9%) and non-elderly patients (71.4%, p=0.318). Additionally, the difference in efficacy of linaclotide in patients who received a reduced dose (80.6%) vs. those who received the recommended dose (75.0%) was not statistically significant (p=0.719). Multivariate analysis revealed that age, gender, and dose were not associated with diarrhea induced by linaclotide treatment. However, concurrent treatment with constipation-inducing medications [odds ratio (OR) 5.79, p=0.047] and linaclotide monotherapy (OR 11.1, p=0.040) were both risk factors contributing to diarrhea. Linaclotide is effective and safe for use in elderly patients. The incidence of diarrhea may increase when linaclotide is administered alone or concurrently used with medications that cause constipation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic constipation | |
| 650 | 4 | |a diarrhea | |
| 650 | 4 | |a elderly patient | |
| 650 | 4 | |a linaclotide | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a linaclotide |2 NLM | |
| 650 | 7 | |a N0TXR0XR5X |2 NLM | |
| 700 | 1 | |a Shimotsubo, Tatsuto |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Kimyo, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakata, Hiromasa |e verfasserin |4 aut | |
| 700 | 1 | |a Fukudo, Masahide |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan |d 1961 |g 141(2021), 2 vom: 22., Seite 255-262 |w (DE-627)NLM000042153 |x 1347-5231 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2021 |g number:2 |g day:22 |g pages:255-262 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/yakushi.20-00176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2021 |e 2 |b 22 |h 255-262 | ||